The oral, whole-cell vaccine for enterotoxigenic Escherichia coli was safe and induced protective efficacy in young children in Gambia.

Each year, tens of thousands of children under 5 die from diarrheal disease caused by enterotoxigenic Escherichia coli (ETEC) ...

Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease (IED) annually, worldwide1,2 Phase 3 clinical trial ...

Enterotoxigenic Escherichia coli (ETEC) remains a leading cause of diarrhoeal illness in developing regions and among travellers. The development of effective vaccines against ETEC is complicated by ...

Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy. The companies ...

As Johnson & Johnson retreats from the vaccine sector, Sanofi is gambling $175 million on the healthcare giant's late-phase E. coli vaccine. J&J has kept studying the candidate while pulling back from ...

Premalignant and malignant lesions of the cervix and other sites related to the human papillomavirus (HPV) infection pose a significant health burden worldwide, especially in developing countries.

Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson, to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli. Under the ...

Sanofi announcesagreementfor potential first-in-class vaccine against extraintestinal pathogenic E. coli Paris, October 3, 2023. Sanofi announces today that it has entered into an agreement with ...